ENGLEWOOD, CO / ACCESSWIRE / May 25, 2021 / Aytu BioPharma, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer health care products, today announced that Josh Disbrow, President and CEO, will present at the next two investor conferences in June:

  • Jefferies Global Healthcare Conference: A live virtual presentation will take place on Tuesday, June 1, 2021 at 3:30 p.m. ET.
  • Webcast link: https://wsw.com/webcast/jeff174/aytu/1881765
  • Raymond James conference on innovations in human health: A live virtual presentation will take place on Wednesday, June 23, 2021 at 12:40 p.m. ET.

These presentations will be available on the conference websites and in the Investors section of the Aytu Bioscience website at the following address: aytubio.com.

About Aytu BioPharma, Inc.
Aytu BioPharma is a specialty pharmaceutical company with a growing business portfolio of prescription therapeutics and consumer health products. The Company’s primary prescription products treat Attention Deficit Hyperactivity Disorder (ADHD) and other common pediatric conditions. Aytu markets products for ADHD Adzenys XR-ODT® (amphetamine) orally disintegrating prolonged-release tablets (see Full Prescribing Information, including boxed WARNING), Cotempla XR-ODT® (methylphenidate) orally disintegrating release tablets Prolonged Prescribing Information (see Full Prescribing Information, including WARNING box) and Adzenys-ER® prolonged-release oral suspension (amphetamine) (see Full Prescribing Information, including WARNING box). The company’s other pediatric products include Karbinal® ER (carbinoxamine maleate), a prolonged-release carbinoxamine (antihistamine) suspension indicated to treat a variety of allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two lines of prescription vitamin products containing combinations of fluoride and vitamins in various formulations for infants and children deficient in fluoride. The evolution of the company has been driven by strategic licenses, transactions based on acquisitions and organic product growth. Aytu is building a complementary therapeutic development pipeline comprising prospective treatment (AR101 / enzastaurin) for vascular Ehlers-Danlos syndrome (vEDS), a rare genetic disorder resulting in high morbidity and dramatically shortened lifespan. There is currently no approved treatment for vEDS. For more information, please visit aytubio.com.

Sarah mccabe
Strong investor relations
[email protected]

SOURCE: Aytu BioPharma, Inc.

See the source version on accesswire.com:

Source link

About The Author

Benjamin Steele

Related Posts

Leave a Reply

Your email address will not be published.